Insiders Love These 3 Highly Shorted Biotech Stocks
posted on
Jan 08, 2013 10:07AM
Edit this title from the Fast Facts Section
Do you consider yourself a contrarian investor? If so, we have just the list for you.
We began by screening the biotech industry for stocks with bearish sentiment from short sellers, with float shorts above 10%.
We then screened these names for those with the confidence of their company insiders, such as members of the board and upper management, with significant net insider purchases over the last six months representing at least 2% of share float. Since most companies only have a handful of company insiders, net insider purchases representing 2% of share float is a big show of confidence in their employer's prospects.
For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.
Do you think these insiders are calling it right? Use this list as a starting point for your own analysis.
1. Infinity Pharmaceuticals, Inc. (INFI): Engages in the discovery and development of medicines for the treatment of cancer and other conditions in the United States. Market cap at $1.45B, most recent closing price at $36.85. Over the last six months, insiders were net buyers of 5,158,726 shares, which represents about 19.81% of the company's 26.04M share float. Float short at 17.58%.
2. MannKind Corp. (MNKD): Focuses on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. Market cap at $611.99M, most recent closing price at $2.49. Over the last six months, insiders were net buyers of 31,269,350 shares, which represents about 33.24% of the company's 94.08M share float. Float short at 15.15%.
3. Theravance Inc. (THRX): Engages in the discovery, development, and commercialization of small molecule medicines for various therapeutic areas, including respiratory disease, bacterial infections, and central nervous system (CNS)/pain. Market cap at $2.11B, most recent closing price at $21.57. Over the last six months, insiders were net buyers of 9,974,883 shares, which represents about 18.3% of the company's 54.52M share float. Float short at 12.27%.
*Insider data sourced from Yahoo! Finance, all other data sourced from Finviz.
http://seekingalpha.com/article/1099411-insiders-love-these-3-highly-shorted-biotech-stocks?source=feed